Juha Puustinen

Juha Puustinen

Auto-generated profile, based on publicly available information

Juha Puustinen

University of Helsinki, Division of Pharmacology and Pharmacotherapy, Satakunta Hospital District, Unit of Neurology, Social Security Center of Pori, Hospital Services, Finland

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
JHJukka Hytönen
Jukka Hytönen
EKElisa Kortela
Elisa Kortela
MWMatti Waris
Matti Waris
JPJuha Puustinen
Juha Puustinen
JSJemiina Salo
Jemiina Salo
JOJarmo Oksi
Jarmo Oksi
Laboratory diagnosis of Lyme neuroborreliosis (LNB) is partly based on the detection of intrathecal Borrelia burgdorferi–specific antibody production (increased antibody index (AI)). However, AI can be negative in patients with early LNB and, conversely, can remain elevated for months after antibiotic treatment. Recent studies suggested that the chemokine CXCL13 in the cerebrospinal fluid (CSF) is a biomarker for active LNB. Also, CSF neopterin-level determination has been used to assess the degree of neuroinflammation in a wide variety of diseases.

1 November 2011 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
JPJuha Puustinen
Juha Puustinen
JNJanne Nurminen
Janne Nurminen
MLMinna Löppönen
Minna Löppönen
TVTero Vahlberg
Tero Vahlberg
RIRaimo Isoaho
Raimo Isoaho
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä
Previous studies have found associations between the use of central nervous system medication and the risk of cognitive decline in the aged. Our aim was to assess whether the use of a single central nervous system (CNS) medication and, on the other hand, the combined use of multiple CNS medications over time are related to the risk of cognitive decline in an older (≥ 65 yrs) population that is cognitively intact at baseline.

22 May 2014 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
RLRitva Lähteenmäki
Ritva Lähteenmäki
JPJuha Puustinen
Juha Puustinen
TVTero Vahlberg
Tero Vahlberg
ALAlan Lyles
Alan Lyles
PNPertti J. Neuvonen
Pertti J. Neuvonen
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä

12 December 2013 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JPJuha Puustinen
Juha Puustinen
RLRitva Lähteenmäki
Ritva Lähteenmäki
PPPäivi Polo-Kantola
Päivi Polo-Kantola
PSPaula Salo
Paula Salo
TVTero Vahlberg
Tero Vahlberg
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä

1 January 2007 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
JPJuha Puustinen
Juha Puustinen
JNJanne Nurminen
Janne Nurminen
MKMatti Kukola
Matti Kukola
TVTero Vahlberg
Tero Vahlberg
KLKari Laine
Kari Laine
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä

6 July 2010 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JNJanne Nurminen
Janne Nurminen
JPJuha Puustinen
Juha Puustinen
MPMaarit Piirtola
Maarit Piirtola
TVTero Vahlberg
Tero Vahlberg
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä
There is evidence that the use of any psychotropic and the concomitant use of two or more benzodiazepines are related to an increased risk of fractures in old age. However, also controversial results exist. The aim was to describe associations between the use of a psychotropic drug, or the concomitant use of two or more of these drugs and the risk of fractures in a population aged 65 years or over.